{"id":53711,"date":"2015-03-14T18:21:51","date_gmt":"2015-03-14T22:21:51","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/apresentacao-de-recursos-do-pagador\/"},"modified":"2025-05-07T15:50:21","modified_gmt":"2025-05-07T19:50:21","slug":"apresentacao-de-recursos-do-pagador","status":"publish","type":"page","link":"https:\/\/www.erdheim-chester.org\/pt-br\/apresentacao-de-recursos-do-pagador\/","title":{"rendered":"Apresenta\u00e7\u00e3o de recursos do pagador"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2024\/12\/Untitled-design-96-1.png&#8221; background_position=&#8221;bottom_center&#8221; background_vertical_offset=&#8221;20%&#8221; custom_padding=&#8221;20px||20px||true|false&#8221; global_module=&#8221;28071&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_dmb_breadcrumbs _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; body_text_color=&#8221;#FFFFFF&#8221; link_text_color=&#8221;#35A4BB&#8221; custom_margin=&#8221;||5px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_dmb_breadcrumbs][et_pb_heading title=&#8221;@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIiwiZW5hYmxlX2h0bWwiOiJvZmYifX0=@&#8221; _builder_version=&#8221;4.27.4&#8243; _dynamic_attributes=&#8221;title&#8221; _module_preset=&#8221;default&#8221; title_font=&#8221;&#8211;et_global_heading_font|300|||||||&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font_size=&#8221;40px&#8221; custom_margin=&#8221;||3px|||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_heading][et_pb_button button_text=&#8221;Entre em contato conosco&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;15px&#8221; button_text_color=&#8221;#C02E43&#8243; button_bg_color=&#8221;rgba(10,22,64,0.53)&#8221; button_border_width=&#8221;0px&#8221; button_icon=&#8221;&#xe60f;||divi||400&#8243; button_icon_color=&#8221;#C02E43&#8243; button_icon_placement=&#8221;left&#8221; button_on_hover=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; filter_opacity__hover_enabled=&#8221;on|hover&#8221; filter_opacity__hover=&#8221;70%&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;section&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row admin_label=&#8221;fila&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text admin_label=&#8221;Text&#8221; _builder_version=&#8221;4.27.4&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p>A maioria dos tratamentos da ECD ainda \u00e9 considerada um tratamento off-label, o que significa que muitas vezes s\u00e3o necess\u00e1rios v\u00e1rios recursos para obter a aprova\u00e7\u00e3o dos pagadores para os tratamentos da ECD nos EUA. Para diminuir a carga desse processo para a equipe m\u00e9dica, foram reunidos exemplos de cartas de apela\u00e7\u00e3o e artigos de peri\u00f3dicos de apoio. As informa\u00e7\u00f5es a seguir fornecer\u00e3o orienta\u00e7\u00e3o sobre o processo de apela\u00e7\u00e3o para que voc\u00ea obtenha cobertura para o tratamento do seu paciente ECD. Para pacientes que vivem fora dos EUA, o processo pode ser diferente para obter aprova\u00e7\u00e3o para um tratamento espec\u00edfico. Entretanto, as mesmas informa\u00e7\u00f5es podem ser \u00fateis para que voc\u00ea obtenha aprova\u00e7\u00e3o para um tratamento espec\u00edfico.    <\/p>\n<p>Trabalhar com as seguradoras, caso a caso, exige muito tempo e esfor\u00e7o. Os medicamentos usados para tratar Erdheim-Chester A doen\u00e7a certamente n\u00e3o \u00e9 exce\u00e7\u00e3o. Alguns dos tratamentos off-label para ECD incluem: Anakinra, dabrafenib, trametinib, cobimetinib, cladribina e metotrexato. A maioria das seguradoras tem uma lista de medicamentos que exigem pr\u00e9-autoriza\u00e7\u00e3o, e esses medicamentos geralmente est\u00e3o nessa lista. Esses medicamentos s\u00e3o caros e dif\u00edceis de serem cobertos pelo paciente sozinho.    <\/p>\n<p>O processo de avalia\u00e7\u00e3o t\u00edpico usado por um pagador \u00e9 que um enfermeiro ou farmac\u00eautico analise a solicita\u00e7\u00e3o e verifique se o medicamento est\u00e1 sendo solicitado para uma indica\u00e7\u00e3o aprovada pela FDA. Quando o medicamento n\u00e3o aparece na lista de aprovados pela FDA, a solicita\u00e7\u00e3o \u00e9 automaticamente negada. Isso coloca a solicita\u00e7\u00e3o em um est\u00e1gio de apela\u00e7\u00e3o, geralmente indo para um diretor m\u00e9dico para avalia\u00e7\u00e3o adicional. H\u00e1 uma enorme variabilidade nesse est\u00e1gio, mas a solicita\u00e7\u00e3o nesse ponto tamb\u00e9m costuma ser negada. Se o medicamento for finalmente aprovado, \u00e0s vezes s\u00e3o necess\u00e1rios at\u00e9 quatro recursos. Quando todos os recursos internos s\u00e3o esgotados, o paciente tem o direito de solicitar uma an\u00e1lise externa. Esse processo geralmente \u00e9 estressante para o paciente e consome muito tempo dos m\u00e9dicos e da equipe.      <\/p>\n<p>Em apoio a esses esfor\u00e7os, foi criada uma cole\u00e7\u00e3o de artigos e uma carta de apela\u00e7\u00e3o para os medicamentos frequentemente prescritos e cuja cobertura \u00e9 negada. Os links a seguir para artigos sobre medicamentos e cartas de apela\u00e7\u00e3o foram criados para ajudar a equipe m\u00e9dica a obter a aprova\u00e7\u00e3o do tratamento pela operadora de seguro do paciente. Outros m\u00e9dicos obtiveram sucesso usando esses formul\u00e1rios na solicita\u00e7\u00e3o. As cartas servem como um modelo de guia para facilitar as apela\u00e7\u00f5es, enquanto os artigos apoiam a solicita\u00e7\u00e3o com fatos e conclus\u00f5es m\u00e9dicas.   <\/p>\n<p><strong>Importante:<\/strong>os m\u00e9dicos e a equipe s\u00e3o aconselhados a usar o c\u00f3digo ICD-10 D76.3, que \u00e9 &#8220;Outras s\u00edndromes de histiocitose&#8221; e\/ou C96A &#8220;Sarcoma histioc\u00edtico&#8221; para determinados estudos de imagem (especialmente PET Scans) em aplica\u00e7\u00f5es para o tratamento e monitoramento do ECD.<\/p>\n<p>Se voc\u00ea precisar de mais assist\u00eancia com esse processo ou quiser fornecer feedback, entre em contato com ECDGA.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;]<\/p>\n\n<table id=\"tablepress-5\" class=\"tablepress tablepress-id-5\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Treatment<\/th><th class=\"column-2\">Example Appeal Letter<\/th><th class=\"column-3\">Supporting peer-reviewed article links\u00a0(listed according to involvement)<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Anakinra (Kineret)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2019\/10\/Letter-Requesting-Anakinra.docx\" target=\"_blank\">Letter Requesting Anakinra Treatment<\/a><\/td><td class=\"column-3\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Rationale+and+efficacy+of+interleukin-1+targeting+in+Erdheim%E2%80%93Chester+disease\" target=\"_blank\">Bone<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Erdheim%E2%80%93Chester+disease+with+cardiac+involvement+successfully+treated+with+anakinra\" target=\"_blank\">Cardiac<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Successful+treatment+of+Erdheim%E2%80%93Chester+disease+with+combination+of+interleukin-1-targeting+drugs+and+high-dose+glucocorticoids\" target=\"_blank\">CNS<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Treatment+of+pediatric+Erdheim-Chester+disease+with+interleukin-1%E2%80%93targeting+drugs\" target=\"_blank\">Pediatric<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Favorable+radiological+outcome+of+skeletal+erdheim-chester+disease+involvement+with+anakinra\" target=\"_blank\">Skeletal<\/a><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Cladribine (Leustatin, Litak or Movectro)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2019\/10\/Letter-Requesting-Cladribine.docx\" target=\"_blank\">Letter Requesting Cladribine Treatment<\/a><\/td><td class=\"column-3\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=24011030\" target=\"_blank\">Comprehensive Review<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Clinical+considerations+and+key+issues+in+the+management+of+patients+with+Erdheim-Chester+Disease%3A+a+seven+case+series\" target=\"_blank\">Multiple Systems<\/a><br \/>\n<a href=\"http:\/\/bjo.bmj.com\/content\/88\/6\/832.full\" target=\"_blank\">Ocular<\/a><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Methotrexate (Trexall or Rheumatrex)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2019\/10\/Letter-Requesting-Methotrexate.docx\" target=\"_blank\">Letter Requesting Methotrexate Treatment<\/a><\/td><td class=\"column-3\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=24362833\" target=\"_blank\">Cardiac<\/a><br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=A+role+for+methotrexate+in+the+management+of+non-infectious+orbital+inflammatory+disease\" target=\"_blank\">Ocular<\/a><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Cobimetinib (Cotellic)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2015\/03\/Letter-Requesting-Coverage-of-Cobimetinib.docx\" target=\"_blank\">Letter Requesting Cobimetinib Treatment<\/a><\/td><td class=\"column-3\"><a href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14284\/abstract;jsessionid=8D21486CF8F795BFE6D019B086E24375.f02t03\" target=\"_blank\">Efficacy of Cobimetinib<\/a><br \/>\n<a href=\"https:\/\/www.nature.com\/articles\/s41586-019-1012-y\" target=\"_blank\">Efficacy of MEK Inhibition<\/a><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Trametinib (Mekinist) and\/or Dabrafenib (Tafinlar)<\/td><td class=\"column-2\"><a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2015\/03\/Letter-Requesting-Coverage-of-Trametinib.docx\" target=\"_blank\">Letter Requesting Trametinib Treatment<\/a><br \/>\n<br \/>\n<a href=\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2015\/03\/Letter-Requesting-Coverage-of-Dabrafenib.docx\" target=\"_blank\">Letter Requesting Dabrafenib Treatment<\/a><\/td><td class=\"column-3\"><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5291734\/\" target=\"_blank\">Efficacy of Trametinib or Dabrafenib<\/a><br \/>\n<a href=\"http:\/\/www.bloodjournal.org\/content\/129\/7\/879.long?sso-checked=true\" target=\"_blank\">Combined Dabrafenib and Trametinib Treatment<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<p>[\/et_pb_text][et_pb_button button_text=&#8221;Entre em contato conosco&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; button_url=&#8221;https:\/\/www.erdheim-chester.org\/pt-br\/entre-em-contato-conosco\/&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[et_pb_dmb_breadcrumbs _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; body_text_color=&#8221;#FFFFFF&#8221; link_text_color=&#8221;#35A4BB&#8221; custom_margin=&#8221;||5px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_dmb_breadcrumbs]A maioria dos tratamentos da ECD ainda \u00e9 considerada um tratamento off-label, o que significa que muitas vezes s\u00e3o necess\u00e1rios v\u00e1rios recursos para [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_wds_title":"","_wds_metadesc":"","_wds_focus-keywords":"","_wds_meta-robots-adv":"","_wds_meta-robots-noindex":false,"_wds_meta-robots-nofollow":false,"_wds_meta-robots-index":false,"_wds_meta-robots-follow":false,"_wds_autolinks-exclude":false,"_wds_canonical":"","_wds_redirect":"","_wds_opengraph":[],"_wds_twitter":[],"cybocfi_hide_featured_image":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-53711","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/pt-br\/wp-json\/wp\/v2\/pages\/53711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/pt-br\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/pt-br\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt-br\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt-br\/wp-json\/wp\/v2\/comments?post=53711"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/pt-br\/wp-json\/wp\/v2\/pages\/53711\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/pt-br\/wp-json\/wp\/v2\/media?parent=53711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}